Watch for resumption of trading post-consolidation and whether the company can sustain a share price above $1.00 for 10 consecutive days by April 13, 2026, to meet Nasdaq's requirement. Monitor for potential dilution in future financings if fundamentals don't improve.
Price Chart
Executive Summary
XORTX Therapeutics is consolidating its shares on a 1:5 basis to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. The move reduces outstanding shares from ~6.96M to ~1.39M and is intended to avoid delisting, with trading expected to resume on a post-consolidation basis by March 27, 2026.
Key Facts
- Share consolidation approved at 1 post-consolidation share for every 5 pre-consolidation shares
- Outstanding shares reduced from 6,962,218 to approximately 1,392,444
- No cash consideration for fractional shares; rounding rules applied
- Consolidation required to meet Nasdaq listing rules (minimum $1.00 share price)
- Trading expected to resume post-consolidation on or about March 27, 2026
- No name change; ticker symbol 'XRTX' remains unchanged
Financial Impact
No direct financial impact — this is a structural adjustment to share count and price. Share price expected to increase fivefold, but market cap remains unchanged at ~$3M.
Risk Factors
- Failure to maintain $1.00 share price post-consolidation could trigger delisting
- Low market cap ($3M) and thin share float may limit institutional interest
- Forward-looking statements carry high uncertainty; clinical programs may not advance as planned
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $1.41 | awaiting T+20 | — | $0.8500 (−39.72%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $0.8500 (+63.20%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $0.8500 (−63.64%) |
Aug 3, 2026 11w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $0.8500 (−60.65%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $0.8500 (−58.74%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
May 19, 2026 22w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $0.8500 (+63.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers